Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

Fig. 1

Time to initial HAQ-DI score response: a OPAL Broaden, b OPAL Beyond (FAS). Score response defined for HAQ-DI as ≥ 0.35-point improvement from baseline (analyzed for patients with baseline HAQ-DI ≥ 0.35). BID, twice daily; FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; Q2W, once every 2 weeks; SC, subcutaneous

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us